Kornimate/medical-research-clean huggingface dataset:
eatable alphabet as a nutrition education tool

Conditions: Child Overnutrition; Child Obesity; Child Nutrition Disorders

Summary: this pilot randomized controlled trial will test the effectiveness of eatable alphabet cards, a child friendly nutrition education tool, on child weight and related behaviors in a clinical sample of 2 to 10-year-old children with overweight/obesity, referred to a pediatric weight management program.

the goal of this research study is to determine whether the use of eatable alphabet cards in addition to standard weight management in a primary care setting will increase vegetable consumption. additional outcomes that will be examined include fruit consumption, child engagement in meal selection and preparation, and clinic follow-up. if the intervention shows a significant effect in the above outcome measures, eatable alphabet cards can be implemented as a standard component of obesity management in primary care settings. it is hypothesized that the intervention will increase vegetable consumption, increase child engagement in meal selection and preparation, and increase clinic follow-up. the study design is randomized control trial, in which the control group includes parent-child dyads receiving care as usual in the weight management program, including nutrition education, and the intervention group includes parent-child dyads receiving care as usual in the weight management program plus eatable alphabet cards in addition to typical nutrition education. all study participants will be families receiving care at the power kids weight management program at 410 lakeville road, with the child between the ages of 2 and 10 who have overweight or obesity. the primary outcome is parent reported frequency of child vegetable consumption. secondary outcomes include: parent reported frequency of child fruit consumption, parent reported child engagement in meal selection/preparation, follow-up weight management visit attendance, and child anthropometric outcomes.

Eligibility criteria:
inclusion criteria: * new patient at cohen children's medical center power kids weight management program (defined as not having been seen by the program within the past 2 years) * child between the ages of 2-10 * english-speaking exclusion criteria: - no appropriate caregiver available for consent.

Keywords: nutrition education pediatric weight management child overweight/obesity fruit and vegetable consumption
the characteristics of blood glucose profile and the changes of hormones in ppdm-c population

Conditions: Chronic Pancreatitis; Diabetes

Summary: the purpose of this study was to explore the characteristics of blood glucose spectrum, changes of endocrine/exocrine pancreatic function and the correlation between them in patients with ppdm-c.

the benefits of this study to participants include: 1. it will help to make early diagnosis or risk screening for the potential related risks and concomitant diseases of the disease; 2. provide necessary suggestions for the treatment and intervention of the disease, or provide useful information for the related research of the disease. 3. we will provide abbott version h dynamic glucose meter and assessment of internal and external secretion function. the researcher will provide professional endocrine related lifestyle and drug guidance for the subjects according to their cgms data. the risks that this study may bring to participants are: there may be some very small risks in specimen collection, including transient pain, local cyanosis, etc. a few people will have mild dizziness or extremely rare needle infection.

Eligibility criteria:
inclusion criteria: * male or female chinese subjects; * was ≥ 18 years old when signing the informed consent; * patients with complete diagnosis of chronic pancreatitis; ④ those who voluntarily signed informed consent; ⑤ those who complete serum samples in multiple centers and put them into storage. exclusion criteria: * patients with impaired glucose tolerance but undiagnosed diabetes; * patients with t1dm related autoimmune markers or other types of dm; * patients with autoimmune pancreatitis, recurrent acute pancreatitis or acute onset of chronic pancreatitis; * patients who underwent pancreatic surgery or related invasive procedures during treatment; * previous or current malignant tumor; ⑥ pregnancy or lactation; ⑦ suffering from severe heart, liver or kidney dysfunction or malignant disease; ⑧ failure to sign informed consent for cognitive impairment or other reasons.

Keywords: chronic pancreatitis ppdm-c cgm
addressing social determinants of health among metro detroit cancer survivors

Conditions: Cancer; Cancer Survivors; Gastrointestinal Cancers; Neuroendocrine Tumors; Multiple Myeloma, Neoplasms

Summary: the goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside in metro detroit, michigan. main questions to answer are: * can we have a completion rate of at least 80% of participants filling out the screening tool? * can we determine procedures for patient referrals based on social needs * can we implement brief interventions based on food access and digital inclusion (ensuring everyone has access to the digital technologies they need to participate in society)

in part 1 of the study, participants will be administered a social screening tool either in person or via telephone. responses to the screening tool will be translated into diagnosis codes which identify non-medical factors that may influence a patient's health status. in part 2 of the study, participants will be referred to community-based resources based on their responses to the social needs screening tool. follow up will be made via telephone call at 2, 4, 6 and 8 weeks.

Eligibility criteria:
inclusion criteria: * 18 years or older * past or current cancer diagnosis * reside in metropolitan detroit (wayne, oakland, macomb counties) * english proficient * actively receiving care through one of karmano's cancer institute's outpatient clinics or post treatment survivors in the detroit research on cancer survivors (rocs) longitudinal cohort study who have reported past food insecurity and agreed to be contacted for further research exclusion criteria: * none
sputum purulence as a predictor of cystic fibrosis exacerbations: a prospective cohort trial.

Conditions: Cystic Fibrosis

Summary: to use the sputum colour chart as a predictor for cystic fibrosis exaerbations

patients will score their sputum purulence daily using three colour charts. they will also score for respiratory and other symptoms. primary analysis will focus on the predicting value of sputum purulence on exacerbations. secondary analysis will evaluate symptoms on exacerbation prediction. a third subanalysis will focus on correlation of daily pollution fluctuations and sputum purulence or symptoms.

Eligibility criteria:
inclusion criteria: * a diagnosis of cystic fibrosis * pseudomonas aeruginosa colonization * at least 2 exacerbations in the previous year * at least 18 years of age exclusion criteria: * colour blindness

Keywords: sputum colour cystic fibrosis pollution
determination of teeth size in a group of egyptian children. a cross sectional study

Conditions: Teeth Size in a Group of Egyptian Children

Summary: determination of the combined mesio-distal widths of the permanent mandibular incisors and that of the maxillary and mandibular canines and premolars in a group of egyptian children in rural areas of sohag governorate: a cross sectional study

study settings: * students will be randomly selected from preparatory schools in rural areas of sohag governorate, seated in the school lap or an empty classroom. * clinical examination will be made in the daylight using disposable diagnostic sets (mirror, and explorer). no diagnostic radiographs will be taken. * operator: master degree's student in pediatric dentistry and dental public health. * full mouth alginate impression will be taken and study models will be poured within one hour with hard dental stone for each subject. * mesio-distal widths of both maxillary and mandibular permanent incisors, canines, first and second premolars will be measured from the study models using digital caliper according to the method described by(moorrees \& reed, 1964) by measuring the greatest distance between the contact points on the proximal surfaces holding the caliper parallel to both occlusal and vestibular surfaces of the tooth.

Eligibility criteria:
inclusion criteria: 1. patients who are apparently medically free from any systemic disease. 2. patients aged between 12-15 years. 3. full set of fully erupted permanent dentition from left 1st permanent molar to right 1st permanent molar. 4. no apparent orthodontics problem. exclusion criteria: 1. patients with craniofacial developmental abnormality. 2. any sensitivity or adverse reactions to any of used materials. 3. patients who refused to participate in the study. 4. teeth with severe malalignment or rotation. 5. teeth with any inaccuracy caused by impression taking, pouring impressions with dental stone or any damage or breakage while the dental casts had been stored. 6. teethwith notable wear, proximal decay, restorations, enamel hypoplasia or crown fracture. 7. teeth with developmental anomalies such as microdont teeth, teeth with extra cusps or big talon cusps, or peg or conical shaped teeth. 8. supernumerary or supplemental teeth (if present)

Keywords: arch lengths, space analysis, arch prediction
prevalence and determinants of subclinical cardiovascular dysfunction in adults with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies

Summary: background: heart failure is a major cause of morbidity and mortality in diabetes mellitus, but its pathophysiology is poorly understood. aim: to determine the prevalence and determinants of subclinical cardiovascular dysfunction in adults with type 2 diabetes (t2d). plan: 518 asymptomatic adults (aged 18-75 years) with t2d will undergo comprehensive evaluation of cardiac structure and function using cardiac mri (cmr) and spectroscopy, echocardiography, ct coronary calcium scoring, exercise tolerance testing and blood sampling. 75 controls will undergo the same evaluation. primary hypothesis: myocardial steatosis is an independent predictor of left ventricular global longitudinal strain. secondary hypotheses: will assess whether cmr is more sensitive to detect early cardiac dysfunction than echocardiography and bnp, and whether cardiac dysfunction is related to peak oxygen consumption. expected value of results: this study will reveal the prevalence and determinants of cardiac dysfunction in t2d, and could provide targets for novel therapies.


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged ≥18 and ≤75 years. * diagnosed with stable type 2 diabetes (determined by: i) formal diagnosis in gp case records, ii) a record of diagnostic oral glucose tolerance test or glycated haemoglobin level ≥6.5%). exclusion criteria: * angina pectoris or limiting dyspnoea (\>nyha ii), * major atherosclerotic disease: symptomatic cad, history of myocardial infarction, previous revascularisation, stroke/transient ischaemic attack or symptomatic peripheral vascular disease. * atrial fibrillation or flutter. * moderate or severe valvular heart disease. * history of heart failure or cardiomyopathy. * type 1 diabetes mellitus (t1dm). * low fasting c-peptide levels suggestive of adult-onset t1dm. * stage iii-v renal disease (estimated glomerular filtration rate ≤30ml/min/1.73m2). * absolute contraindications to cmr. importantly, patients with subclinical cad, and other common comorbidities such as obesity and hypertension, will not be excluded from this study. this will enable us to evaluate the contribution of cad to myocardial dysfunction in diabetes and ensures our study group is representative of the general population with diabetes. similarly, as mild dyspnoea is extremely common and non-specific participants with mild dyspnoea will be included.

Keywords: type 2 diabetes diabetic cardiomyopathy cardiovascular magnetic resonance
immune markers in pediatric itp on second line therapy

Conditions: ITP - Immune Thrombocytopenia

Summary: immune thrombocytopenia (itp) is a common autoimmune disease characterized by low platelet count and increased risk of bleeding. it affects approximately 50 to 100 cases per million people per year, with children accounting for half of the cases.

antiplatelet factors in the plasma of itp patients, specifically igg, have been attributed to platelet destruction through phagocytosis or complement-mediated lysis. however, these antibodies are only present in 60-70% of itp patients, suggesting that other mechanisms may be involved in platelet destruction. b lymphocytes play a critical role in immune responses through antibody production, antigen presentation to t cells, and cytokine secretion. cd4+ t helper cells play a crucial role in supporting b cell development into antibody-secreting plasma cells. furthermore, evidence of auto reactive cd4+ t cells targeting platelet epitopes has been reported. it was found that there is clonal expansion of a particular subset of cd8+ t cells, known as terminally differentiated effector memory t cells (temra cells), in refractory itp. furthermore, cd8+ t cells induce platelet activation and apoptosis in an antibody-independent mechanism for refractory thrombocytopenia that may be amenable to therapeutic targeting. ifn-γ is an important cytokine involved in host defence and immune regulation. it is primarily produced by t helper, cytotoxic t, and natural killer cells. dysregulated secretion of ifn-γ has been implicated in the development of autoimmune disorders. initial studies on itp focused on the role of autoantibodies. therefore, drug discovery efforts have focused on suppressing aberrant humoral immunity through b cell depletion, disruption of immunoreceptor, and inhibition of autoantibody activity. by comparing the marker expression in different treatment response groups, the investigator can potentially identify markers that may serve as predictive or prognostic indicators of treatment response. this information could be valuable for guiding treatment decisions and optimizing patient outcomes in pediatric itp.

Eligibility criteria:
inclusion criteria: * pediatric patients diagnosed with immune thrombocytopenia who are undergoing second line therapy with either eltrombopag or romiplostim. exclusion criteria: * include acute immune thrombocytopenic children receiving first line therapy and those with secondary immune thrombocytopenia.
an efficacy, pharmacokinetics, safety and tolerability study of tmc435 as part of a treatment regimen for hepatitis c-infected patients

Conditions: Hepatitis C, Chronic

Summary: the purpose of this study is to provide confirmatory efficacy and safety data of tmc435 as part of a treatment regimen including peginterferon-alpha (pegifnα-2a) and ribavirin (rbv) in patients with genotype 1 hepatitis c virus (hcv) infection.

this is a multicenter, randomized (study drug is assigned by chance), double-blind (neither sponsor, physician nor patient knows the name of the assigned study drug), phase iii study to compare the efficacy, tolerability and safety of tmc435 (in development for treatment of chronic hepatitis c virus \[hcv\] infection) versus placebo (a preparation containing no drug used as control) as part of a treatment regimen including peginterferon-alpha (pegifnα-2a) and ribavirin (rbv) (both current therapies for hcv) in adult treatment-naïve patients (patients who have never taken hcv medications) with genotype 1 hepatitis c virus (hcv) infection. the study will consist of a screening period with a maximum duration of 6 weeks, a response guided 24- or 48-week (tmc435 treatment groups) or 48-week (control group) treatment period, and a post-therapy follow-up period up to 72 weeks after the start of treatment. patients will be randomly assigned in a 1:1:1 fashion to receive tmc435 or placebo, stratified by hcv genotype 1 subtype and il28b genotype within each country. in the first 24 weeks, patients will receive 12 weeks tmc435 100 or 150 mg or placebo once-daily (q.d.) plus pegifnα-2a plus rbv, after which they will continue with pegifnα-2a and rbv. response-guided treatment criteria will be used to determine pegifnα-2a and rbv total treatment duration of 24 or 48 weeks for patients in the tmc435 treatment groups. in the control group, all patients will be required to complete 48 weeks of treatment with pegifnα-2a and rbv. in all 3 treatment groups, there will be a post-therapy follow-up period up to 72 weeks after the start of treatment. the total study duration for each patient will be a maximum of 78 weeks (including the 6-week screening period).

Eligibility criteria:
inclusion criteria: * a liver biopsy within 3 years prior to the screening visit (or between screening and day of randomization) with histology consistent with chronic hepatitis c virus (hcv) infection * presence of contraindications for a liver biopsy in patients who are otherwise deemed eligible for participation does not exclude the patient from participation * genotype 1 hcv infection (confirmed at screening) * plasma hcv rna of \> 10,000 iu/ml at screening exclusion criteria: * prior treatment with any approved or investigational drug for the treatment of hepatitis c * co-infection with hepatitis b virus or human immunodeficiency virus (hiv)

Keywords: hepatitis c, chronic tmc435 ribavirin peginterferon-alpha (pegifnα-2a)
28-day mortality prediction for critically ill patients in the intensive care unit: physician-nurse vs. score

Conditions: Mortality Prediction

Summary: there are several scores for predicting mortality within 28 days in the intensive care unit, including apache 2, mpm 2 and mods. these models for predicting mortality can help intensive care physicians to identify patients at high risk of mortality, thus helping them in the decision regarding their admission to the icu and the management of their care during hospitalization. however, it is not entirely clear whether these models can predict mortality better than an experienced icu physician or nurse. the purpose of the study is to compare the ability of a senior icu physician and nurse to predict mortality within 28 days in intensive care patients and between the predictive ability of three models for mortality prediction, as well as to investigate what were the parameters that particularly influenced the mortality prediction of the medical and nursing staff. the study will be performed as a prospective observational study and will include approximately 2000 patients. for each patient admitted to intensive care, the risk of mortality will be calculated according to apache 2, mpm 2 and mods. in addition, an independent evaluation by 3 specialist icu physicians and an experienced icu nurse will be carried out. the medical and nursing staff's reasons for the risk provided by them will be presented.


Eligibility criteria:
inclusion criteria: * all patients admitted to the icu between 1.1.2025 and 1.1.2027. exclusion criteria: * patients who were hospitalized in the icu for less than 72 hours.
switching the non-nucleoside reverse transcriptase inhibitor (nnrti) or protease inhibitor (pi) to maraviroc in hiv subjects

Conditions: HIV; HIV Infections

Summary: patients with hiv-1 infection on haart regimen including 2 nrti/ntrtis plus one of the following : 1 pi/ritonavir or atv/unboosted or 1 nnrti, will be randomized to switch from the nnrti/pi to maraviroc (300 mg /12 h) or to continue with the same approach.

this is a 48 week randomized, prospective, controlled, open-label, proof-of-concept pilot clinical trial. patients with hiv-1 infection on haart regimen including 2 nrti/ntrtis plus one of the following : 1 pi/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir) or atv/unboosted (in a regimen without tenofovir) or 1 nnrti (nevirapine or efavirenz). patients will be randomized to switch from the nnrti/pi to maraviroc (300 mg /12 h) or to continue with the same approach. the primary endpoint would be the percentage of patients who maintain virological suppression at week 48.

Eligibility criteria:
inclusion criteria: 1. hiv-1 infected adults (=/+18 years old). 2. patient having a diagnosis of hiv infection, on stable haart including 2 nrti/ntrtis plus one of the following: 1 pi/ritonavir or atv/unboosted or 1 nnrti. 3. undetectable plasma hiv-1 rna (vl \< 50 copies/ml) while on haart. 4. patient having at least one of the following conditions: * antiretroviral-related gastrointestinal disturbances, or * low patient's satisfaction associated with the current regimen posology (ritonavir use, ritonavir intolerance...), or * any toxicity drug related. 5. nadir cd4 cell count \> 350 cells/mm3. 6. absence of resistance mutations in the rt or pr by (trugenetm) 7. good treatment adherence. 8. voluntary written informed consent. exclusion criteria: 1. virologic failure to a previous antiretroviral regimen. 2. any antiretroviral resistance mutation in a previous resistance test. 3. dual/mixed or x4 viruses detected at any time point, including the pre-treatment es-trofile test of the pbmc test done before treatment switch. 4. acute infections or uncontrolled chronic infection in the 2 months previous to the inclusion. 5. pregnancy or fertile women willing to be pregnant.

Keywords: switching maraviroc virological efficacy lipid profile tropism
observational study of the development of low back pain after total hip arthroplasty.

Conditions: Low Back Pain; Hip Osteoarthritis; Arthropathy of Hip

Summary: the investigators are going to observe the appearance of low back pain in patients who have undergone hip prosthesis surgery.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age and under 70 years of age, intervened by cta due to oac since january 1, 2010 and before january 1, 2021 and who have developed subsequent lumbar pathology. exclusion criteria (relative/absolute): * under 18 years of age at the time of the intervention. * over 70 years of age at the time of surgery. * previous low back pain. * bilateral cta. * previous lower limb or axial fracture. * dysmetria. * vertebral surgery prior to cta. * scoliosis. * scheuermann's disease. * neoplasms affecting axial skeleton. * bone infections. * neurodegenerative disease. * cta secondary to fractures. * cta replacements.

Keywords: pain low back pain psoas muscle hip arthroplasty
36-month clinical evaluation of a universal adhesive

Conditions: Non-Carious Cervical Lesions

Summary: the aim of this clinical trial was to evaluate and compare the performance of a universal adhesive with different adhesive strategies in the restoration of non-carious cervical lesions (nccls) over a 36-month period.

one hundred sixty-five nccls in 35 patients (13 female, 22 male) with at least 3 lesions were included in this study. three groups were formed according to adhesive strategies used (n=55): selective-etch mode; etch-and-rinse mode (er); or self-etch (se) mode of a universal adhesive, single bond universal. the same nanofilled resin composite, filtek ultimate was used for all restorations by a single operator. the restorations were evaluated by two calibrated examiners at baseline and at 6-, 12-, 18-, 24- and 36- months in accordance with the modified usphs criteria. the chi-square test was used for intergroup, the cochran q test was used for intragroup comparison.

Eligibility criteria:
inclusion criteria: * over 18 years old * good oral hygiene * available for recall * at least 20 teeth under occlusion * the presence of at least three non-carious cervical lesions exclusion criteria: * poor oral hygiene * bruxism habits * severe or chronic periodontitis * if the teeth selected for study, were nonvital, or had any restorations on other surfaces were not included.

Keywords: non-carious cervical lesions universal adhesive